Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.

Thromb Res

Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark; Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. Electronic address:

Published: June 2021

Background: Multiple myeloma (MM) and its precursor condition, monoclonal gammopathy of undetermined significance (MGUS) have an increased risk of thrombotic events, especially during anti-myeloma treatment. Many different underlying causes for this hypercoagulability have been suggested, but current techniques to identify abnormalities in these patients are sparse and inefficient. The aim of this study was to assess the hypercoagulability in MGUS and MM patients through various coagulation analyses and identify changes in the MM patients throughout their treatment regimen.

Materials And Methods: Platelet-free plasma from 38 MM patients, 19 MGUS patients and 34 healthy controls were tested for hypercoagulability using calibrated automated thrombogram, a procoagulant phospholipid assay, a microvesicle-associated (MV) tissue factor (TF) assay, and a cell-free deoxyribonucleic acid (cf-DNA) assay as a surrogate measurement for neutrophil extracellular traps (NETs).

Results: MGUS and MM patients both had elevated thrombin generation and procoagulant phospholipid activity in comparison to the control subjects. MM, and partly MGUS, showed increased MV-TF activity, however, only MM had increased levels of the cf-DNA.

Conclusions: Here we demonstrated that hypercoagulability was present in patients with MGUS and MM through increased thrombin generation, possibly due to higher TF and procoagulant phospholipids (PPL) activity. This may be associated to MVs and, for MM patients, be attributed to procoagulant NETs activity; however, this remains to be determined.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.thromres.2021.03.015DOI Listing

Publication Analysis

Top Keywords

mgus increased
12
mgus patients
12
patients
9
abnormalities patients
8
multiple myeloma
8
monoclonal gammopathy
8
gammopathy undetermined
8
undetermined significance
8
patients mgus
8
procoagulant phospholipid
8

Similar Publications

Hypergammaglobulinemia is a sign of B cell and plasma cell hyperactivity marked by elevated levels of gamma globulins, proteins within the gamma fraction of serum electrophoresis, linked to diseases like acute hepatitis, Hodgkin's lymphoma, autoimmune conditions, and neoplasms. Monoclonal gammopathy of undetermined significance (MGUS) is found in 3.2% of individuals over 50 and 5.

View Article and Find Full Text PDF

Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review.

Clin Lymphoma Myeloma Leuk

December 2024

Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT. Electronic address:

Monoclonal gammopathy of undetermined significance (MGUS) is a pre-malignant condition of multiple myeloma (MM). Evidence suggested old age, black race, male gender, and obesity as risk factors for MGUS development; however, whether they are associated with an increased risk of progression to MM among patients with MGUS is unclear. A systematic search of PUBMED and EMBASE for cohort studies investigating the association between age/race/gender/obesity and progression to MM.

View Article and Find Full Text PDF

Monoclonal gammopathy of undetermined significance (MGUS) is the asymptomatic precursor of multiple myeloma and related diseases but has also been associated with thrombosis. Prior studies have not been based on screened cohorts leading to bias. We assessed the risk of thrombosis in a cohort of 75 422 individuals over 40 years old who were screened for MGUS in Iceland.

View Article and Find Full Text PDF

Effect of adipose tissue on the development of multiple myeloma.

Mol Biol Rep

December 2024

Department of Histology, Medical University of Gdańsk, Dębinki 1, 80-211, Gdańsk, Poland.

Article Synopsis
  • Multiple myeloma (MM) is a type of cancer involving the uncontrolled growth of abnormal plasma cells and affects the bone tissue microenvironment.
  • Bone marrow adipose tissue (BMAT) plays a significant role in MM progression, influencing the cancer through various biological pathways, and obesity can exacerbate this by increasing BMAT mass and disrupting bone health.
  • Factors such as impaired fat metabolism and increased harmful substances from fat cells are linked to the progression of MM, prompting a thorough review of existing research on the connection between excess fat and the risk of developing this cancer.
View Article and Find Full Text PDF

Light-chain (LC) monoclonal gammopathy of undetermined significance (MGUS) is a precursor of multiple myeloma (MM) and related conditions. LC-MGUS is characterized by free light-chain (FLC) levels outside defined reference intervals, indirectly indicating underlying plasma cell (PC) monoclonality. Next-generation flow cytometry (NGF) was used to evaluate clonal PC presence in bone marrow (BM) samples from individuals with LC-MGUS in the iStopMM study, aiming to assess the predictive value of the FLC ratio for clonal PC presence and its prognostic implications.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!